METHOD FOR PREVENTING BENIGN PROSTATE HYPERPLASIA IN MALE PATIENTS DISTINGUISHED BY PARTIAL ANDROGEN AGE-SPECIFIC DEFICIENCY (PADAM)

FIELD: medicine. ^ SUBSTANCE: method involves reducing blood plasma level of prolactin, growth somatotropic hormone, insulin-like growth factor-1, adrenocorticotropic hormone, hydrocortisone, 5alpha-dihydrotestosterone, 17beta-estradiol, insulin, glucagons, glucose on the empty stomach, 1,25(OH)2D3,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MAZUROV V.I, KARPISHCHENKO A.I, PECHERSKIJ A.V, SEMIGLAZOV V.F
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	DIAGNOSIS HUMAN NECESSITIES HYGIENE IDENTIFICATION MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SURGERY
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine. ^ SUBSTANCE: method involves reducing blood plasma level of prolactin, growth somatotropic hormone, insulin-like growth factor-1, adrenocorticotropic hormone, hydrocortisone, 5alpha-dihydrotestosterone, 17beta-estradiol, insulin, glucagons, glucose on the empty stomach, 1,25(OH)2D3, epidermal growth factor, general fibroblast growth factor, tumor necrosis factor alpha, interleykine 1alpha, interleykine 1beta, interleykine 6, increasing blood plasma level of transforming growth factor beta by individual selection of testosterone preparation dose providing normalized level of lutropin, general testosterone, free testosterone, globulin binding sex hormones, free androgen index, 5alpha-dihydrotestosterone, 17beta-estradiol, recovery of pulsating lutropin and general testosterone secretion. ^ EFFECT: enhanced effectiveness in acting upon pathogenic aspects of benign prostate hyperplasia prophylaxis.